Skip to main content

Table 2 Markers of uncontrolled asthma during 6-month follow-up (MTL-4 group, n = 51 and ICS group, n = 768)

From: Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study

Exacerbation and/or acute loss of asthma control* (≥1)

MTL-4 group n (%)

ICS group n (%)

Markers of exacerbation:

  

Dispensation of oral corticosteroids

25 (49.0%)

470 (61.2%)

Asthma-related hospitalizations

2 (3.9%)

37 (4.8%)

Markers of acute loss of asthma control**

31 (60.8%)

445 (57.9%)

Any of the above

40 (78.4%)

605 (78.8%)

  1. *Not mutually exclusive; an infant could have one or more markers of exacerbation during the period.
  2. **Addition of short-acting beta agonists to existing respiratory therapy, switch to higher dose ICS therapy, or switch to nebulized CS.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us